Literature DB >> 8477574

Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem?

M L Sanchez1, K K Flint, R N Jones.   

Abstract

A total of 2189 staphylococcal strains at the University of Iowa Hospitals and Clinics (Iowa City, IA) were initially screened to determine the incidence of constitutive (29.8%) and potential inducible macrolide-lincosamide-streptogramin (MLS) resistance (11.3%). Staphylococcus haemolyticus and S. epidermidis (62.5% and 55.3%) showed the highest incidence of constitutive resistance. Staphylococcus hominis had the highest incidence of inducible resistance (40.6%), while S. aureus had the lowest rate for both resistance types. The overall ratio of constitutive-inducible MLS resistance was 4:1. Among strains initially speciated using the Vitek System GPI card, there was only a 69% species identification reproducibility, and 78% accuracy versus a reference identification method. A random sample of 105 Staphylococcus spp. isolates with discordant macrolide (erythromycin resistant) and lincosamide (clindamycin susceptible) susceptibility patterns were tested against 16 antimicrobial agents by using a reference broth microdilution method. All erythromycin-resistant Staphylococcus spp. were also resistant to other 14-member macrolides and azithromycin, while all organisms remained susceptible to clindamycin, rifampin, vancomycin, and the streptogramin compounds (RP59500 and virginiamycin). Resistance to teicoplanin was identified among some oxacillin-resistant S. haemolyticus strains. Of 105 isolates, 65 (62%) showed inducible MLS resistance, 28 (27%) were noninducible, and 12 (11%) were either fully susceptible or resistant to the MLS drugs (Vitek System interpretation errors). MLS disk induction tests revealed two inducible resistance phenotypes: ML and MLS. Staphylococcus aureus showed the highest inducible resistance rate at 95% with an MLS-predominant pattern. In contrast, endemic S. haemolyticus isolates did not demonstrate inducible resistance that is, efflux-mediated erythromycin resistance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477574     DOI: 10.1016/0732-8893(93)90111-j

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  21 in total

1.  Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Authors:  A M Nilius; M H Bui; L Almer; D Hensey-Rudloff; J Beyer; Z Ma; Y S Or; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.

Authors:  G Lina; A Quaglia; M E Reverdy; R Leclercq; F Vandenesch; J Etienne
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing.

Authors:  J H Jorgensen; S A Crawford; M L McElmeel; K R Fiebelkorn
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Selection of strains for quality assessment of the disk induction method for detection of inducible clindamycin resistance in Staphylococci: a CLSI collaborative study.

Authors:  Adrian M Zelazny; Mary Jane Ferraro; Anita Glennen; Janet F Hindler; Linda M Mann; Susan Munro; Patrick R Murray; L Barth Reller; Fred C Tenover; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

5.  Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus.

Authors:  Christine D Steward; Patti M Raney; Allison K Morrell; Portia P Williams; Linda K McDougal; Laura Jevitt; John E McGowan; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

6.  Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure.

Authors:  Todd P Levin; Byungse Suh; Peter Axelrod; Allan L Truant; Thomas Fekete
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  M J Rybak; H H Houlihan; R C Mercier; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates.

Authors:  Mukesh Patel; Ken B Waites; Stephen A Moser; Gretchen A Cloud; Craig J Hoesley
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

9.  Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Authors:  Vlatka Matic; Klaudia Kosowska; Bulent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim L Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

10.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.